Search is Powered by Google
Cancer / Oncology News

EGFR-Targeting Antibody Licensed To Abbott

Main Category: Cancer / Oncology
Also Included In: Pharma Industry / Biotech Industry;  Biology / Biochemistry
Article Date: 18 Nov 2008 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 and a half stars

3.5 (2 votes)

Health Professional:1 star

1 (1 votes)

Article Opinions: 0 posts

The international Ludwig Institute for Cancer Research (LICR) has announced that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate, antibody 806, to pharmaceutical company Abbott.

The 806 antibody targets the EGFR cell surface protein but - crucially - only when the protein is over-expressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers. Current therapies that target EGFR, such as Tarceva® and Erbitux®, cause side-effects by targeting EGFR both when it is overexpressed on cancer cells and when it is present in usual amounts on normal cells.

According to Prof. Andrew M. Scott, Director of the LICR Melbourne Centre, the ability of the 806 antibody to distinguish between normal EGFR and over-expressed EGFR made it the first example of a second-generation of targeting antibodies. "Our phase I clinical trial showed very clearly that the 806 antibody exquisitely targets a variety of tumours, including brain, lung, head and neck, skin and colorectal cancers. Most importantly, we demonstrated that the antibody does not bind to any normal tissues or cause any significant toxicity. This suggests the 806 antibody will have anti-tumour effects without the side effects commonly seen following treatment with other EGFR-targeting therapies."

The 806 antibody was generated in the laboratory of Dr. Lloyd J. Old, Director of the LICR New York Branch, to bind specifically to a mutant EGFR found in glioblastoma, a particular type of brain tumour. However, detailed characterization by the Institute's branches in Melbourne, New York and San Diego showed that the 806 antibody binds also to normal EGFR only when it is over-expressed, such as on cancer cells.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Sarah L. White
Ludwig Institute for Cancer Research

View drug information on Erbitux; Tarceva.





Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...